Last reviewed · How we verify

NCT07332715

Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients

Not yet recruiting Last updated 13 January 2026
What this trial tests

trial testing Non-interventional / Observational Study in Sepsis-Related Mortality in 80 participants. Not yet recruiting.

Timeline
15 January 2026
Primary endpoint
15 May 2026
31 May 2026

Quick facts

Lead sponsorIstinye University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment80
Start date15 January 2026
Primary completion15 May 2026
Estimated completion31 May 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istinye University

Who can join

65 and older, any sex, with Sepsis-Related Mortality or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis. This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included. The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Istinye University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07332715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing